April 1st, 2026 | MCP & Agentic AI
Every week, a new AI tool promises to "transform healthcare." Most of them are polished wrappers around a general-purpose LLM with a medical disclaimer buried in the footer.
FDB's MedProof MCP™ is not that.
On March 31, 2026, First Databank (FDB) announced the general availability of FDB MedProof MCP™ — the first Model Context Protocol server built specifically for AI agent-driven medication decisions. Not a chatbot. Not a demo. Production infrastructure, live today, already running inside platforms that touch over 100 million patients.
The Problem Nobody Was Solving Correctly
Here's a number worth sitting with: pharmacists spend 30–40% of every shift manually checking medication orders.
That's nearly half a working day, every day, spent on verification tasks that are mind-numbing and high-stakes at the same time. Physicians aren't doing much better. After every patient encounter, they're manually re-entering prescription data into EMRs — transcribing what was just discussed verbally into structured codified orders. By hand. In 2026.
The frustrating part? Healthcare has had "AI" in it for years. But most of that AI couldn't actually do anything inside clinical workflows. It could flag things. Suggest things. But the moment a decision needed grounding in real drug knowledge — dosages, contraindications, formulary status, patient context — the AI hit a wall.
The wall wasn't intelligence. It was infrastructure.
What MCP Changes (For Those New to It)
Model Context Protocol (MCP) is an open standard that defines how AI agents connect to external tools, data sources, and services. Think of it as USB-C for AI: one plug that any agent can use to talk to any capable system, without a custom integration built from scratch every time.
Before MCP, if a healthcare company wanted to plug an LLM into their drug knowledge database, they'd build a bespoke API integration. Then another one for the next agent. Then maintain both. Then rebuild when the AI layer changed. It was fragile, slow, and expensive in a domain that can't afford fragile.
MCP collapses that complexity. One server. Any compliant agent can connect. The drug knowledge is current, patient-specific, and accessible — without the integration work that used to take months to get right.
FDB saw this coming early. They first piloted their MCP server in October 2025. The response was strong enough that by March 2026, they had a generally available product, now formally named FDB MedProof MCP™.
What FDB MedProof MCP Actually Does
FDB isn't a startup. They're the company whose drug knowledge already sits inside the majority of US hospitals, pharmacies, and physician practices. When their data flags a dangerous interaction, clinicians act on it. That credibility took decades to build.
MedProof MCP puts that same intelligence in reach of AI agents — in patient-specific context, across every major EHR.
The server supports a few key workflows:
Prescription Automation. An agent listens to a doctor-patient conversation via ambient audio, pulls the relevant medication intent, and pre-populates a structured prescription order inside the EMR. The physician reviews, confirms, or adjusts. No re-typing, no transcription step.
Pharmacy Order Verification. Instead of a pharmacist manually pulling up charts to verify every single order, an agent runs the checks and surfaces only the cases that genuinely need a human call.
Medication Reconciliation. Building an accurate list of a patient's current medications across fragmented records is one of those tasks that sounds simple and takes forever. Agents handle it as part of standard workflow.
Ambient Listening. Medication insights surface during clinical conversations in real time, so the physician gets the relevant context while still in the room — not after they've moved to the next patient.
All of this runs through one connection point. Developers don't rebuild drug knowledge access from scratch for every new agent they ship.
The Three Products to Know
FDB is shipping three things under this umbrella:
FDB MedProof MCP™ — The infrastructure layer. Connects AI agents to FDB's drug knowledge database across Epic, athenahealth, eClinicalWorks, MEDITECH, Oracle Health/Cerner, and others. This is what everything else sits on top of, including third-party tools.
FDB Script Agent™ — A prescription automation agent for ambulatory settings. Doctor speaks, prescription gets structured and queued. The physician reviews it, not types it.
FDB VerifyAssist™ — An inpatient pharmacy verification assistant. Runs drug checks at the right moment, cutting out the chart-digging that currently eats up so much pharmacist time.
Each integrates via MCP or traditional API, so health tech teams can adopt at whatever layer makes sense for their current stack.
Real Adoption, Not Vaporware
The most credible signal is who's already building on it.
Artera — a patient communications platform serving over 1,000 healthcare organizations and more than 100 million patients a year — is one of the early adopters. Their platform handles billions of messages across major EHR systems, and they're already using MedProof MCP as a foundation for agentic workflows.
Zach Wood, Chief Product and Strategy Officer at Artera, described it as "a critical unlock" — not because it brought new drug knowledge, but because it made that knowledge reliably accessible to agents in a way that wasn't possible before. Secure, consistent, and fast enough to actually prototype on.
That last part matters more than it sounds. In healthcare, compliance cycles are long and trust is earned slowly. If teams can go from idea to validated prototype in weeks instead of months, that changes what's worth building.
Why This Is Bigger Than One Launch
FDB's move here is worth thinking through carefully.
For decades, their model was to license drug knowledge to health IT vendors via SDKs and APIs. That worked well when software was built once and updated slowly. The AI era broke that model. Agents are dynamic — they spin up, query external systems, and act, all inside a single workflow. Static API integrations weren't designed for that rhythm.
By building a native MCP server, FDB is repositioning from data supplier to something closer to core infrastructure. They're not just the source of drug knowledge anymore. They're the layer that any healthcare AI agent needs to plug into to work safely.
That's a different business. And a different kind of defensibility.
Virginia Halsey, SVP of Strategy and Product at FDB, described this as moving "beyond data delivery to more intelligent, workflow-integrated solutions." The translation: we're not selling data exports anymore, we're becoming the plumbing.
What This Probably Means Going Forward
A few things seem worth watching as MedProof MCP settles in:
The infrastructure layer is starting to separate clearly from the application layer. There will be specialized MCP servers for drug knowledge, clinical records, lab data, billing. AI agents will connect across all of them. The companies that own those infrastructure positions will have real leverage over anything built on top — which means this isn't just a product launch, it's a land grab.
Safety is becoming a genuine differentiator, not just a checkbox. The healthcare AI market has a long list of products that failed because clinicians didn't trust them. FDB's argument is that grounding agents in validated drug knowledge — instead of letting an LLM guess at interactions from training data — is what earns that trust. It's a reasonable argument, and one that's harder to replicate than it sounds.
If MCP is getting production traction in healthcare — the hardest possible domain for this stuff — finance and legal and insurance will follow. Not because they want to copy healthcare, but because the same infrastructure problem exists everywhere regulated.
The Bottom Line
FDB MedProof MCP™ is what it looks like when a legacy data company actually understands what agentic AI requires — and builds for it instead of bolting a chat interface onto an existing product.
Pharmacists get time back. Physicians stop re-entering what they already said out loud. Developers get a foundation that doesn't require rebuilding every time the AI layer shifts.
David Delaney, President of FDB, put it plainly: "This is how AI stops being a promise and starts being infrastructure."
Hard to argue with that. The interesting question now is who builds what on top of it.
Follow us for daily coverage of what's actually happening in MCP and agentic AI.
Top comments (0)